 In this study, lumateperone 42 mg showed significant reduction in depressive symptoms compared to placebo in patients with a major depressive episode associated with bipolar I or bipolar II disorder and a favorable safety and tolerability profile. These anti-depressant effects were statistically significant in both bipolar I and bipolar II disorder subgroup populations 